{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:19:49Z","timestamp":1699402789606},"reference-count":5,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,11]],"date-time":"2015-09-11T00:00:00Z","timestamp":1441929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:p>Progressive multifocal leukoencephalopathy (PML) has been observed after the use of several medicines, including monoclonal antibodies. As these drugs play important roles in the therapeutic armamentarium, it is important to address the challenges that this severe adverse reaction poses to the safe use of medicines. Considering the need for consistent outcomes of regulatory decisions, the European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) used PML as an example to develop a systematic approach to labeling and risk minimization.<\/jats:p>","DOI":"10.1002\/cpt.199","type":"journal-article","created":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T23:49:01Z","timestamp":1438904941000},"page":"502-505","source":"Crossref","is-referenced-by-count":4,"title":["Strategy in Regulatory Decision\u2010Making for Management of Progressive Multifocal Leukoencephalopathy"],"prefix":"10.1111","volume":"98","author":[{"given":"A","family":"Segec","sequence":"first","affiliation":[{"name":"European Medicines Agency London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Keller\u2010Stanislawski","sequence":"additional","affiliation":[{"name":"Department of Safety of Medicinal Products and Medical Devices, Paul\u2010Ehrlich Institute Federal Institute for Vaccines and Biomedicines Langen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NS","family":"Vermeer","sequence":"additional","affiliation":[{"name":"Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology Utrecht University Utrecht The Netherlands"},{"name":"Medicines Evaluation Board Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Macchiarulo","sequence":"additional","affiliation":[{"name":"Agenzia Italiana del Farmaco (AIFA) Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SM","family":"Straus","sequence":"additional","affiliation":[{"name":"Medicines Evaluation Board Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Hidalgo\u2010Simon","sequence":"additional","affiliation":[{"name":"European Medicines Agency London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ML","family":"De Bruin","sequence":"additional","affiliation":[{"name":"Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology Utrecht University Utrecht The Netherlands"},{"name":"Medicines Evaluation Board Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,9,11]]},"reference":[{"key":"e_1_2_6_1_1","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12128"},{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.4"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-302478"},{"key":"e_1_2_6_4_1","unstructured":"European Commission.A Guideline on Summary of Product Characteristics (SmPC). September 2009. <http:\/\/ec.europa.eu\/health\/files\/eudralex\/vol\u20102\/c\/smpc_guideline_rev2_en.pdf>. Accessed 3 February2015."},{"key":"e_1_2_6_5_1","unstructured":"Guideline on Good Pharmacovigilance Practices (GVP) Module V \u2013 Risk Management Systems (Rev 1)5 April 2014 EMA\/838713\/2011 Rev 1*. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500129134.pdf>. Accessed 2 March2015."}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.199","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:27:49Z","timestamp":1699363669000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,11]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1002\/cpt.199"],"URL":"https:\/\/doi.org\/10.1002\/cpt.199","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,11]]}}}